Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14636998 | 0.79 | BTK (0.41) | BTKTNK2RETKDRRAF1 | |
| SCHEMBL31330580 | 0.78 | TNK2 (0.40) | BTKTNK2 | |
| SCHEMBL14630510 | 0.77 | BTK (0.48) | BTKTNK2SRC | |
| SCHEMBL31330631 | 0.74 | TNK2 (0.39) | BTKTNK2SRC | |
| SCHEMBL23044547 | 0.72 | BTK (0.48) | BTKTNK2SRC | |
| SCHEMBL31330542 | 0.72 | RET (0.41) | BTKTNK2RETKDR | |
| SCHEMBL3540179 | 0.72 | NUDT1 (0.36) | BTKTNK2SRC | |
| SCHEMBL28623986 | 0.71 | BTK (0.42) | BTKTNK2RETKDRSRC | |
| SCHEMBL14636369 | 0.71 | BTK (0.42) | BTKTNK2RETKDRSRC | |
| SCHEMBL17800082 | 0.70 | TNK2 (0.38) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331729-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME (NL) | 2023-10-19 | — | — | US | disclosed |
| EP-4249076-A2 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | Merck Sharp & Dohme B.V. (NL) | 2023-09-27 | — | — | EP | disclosed |
| EP-3495368-B1 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | MERCK SHARP & DOHME (NL) | 2023-05-31 | — | — | EP | disclosed |
| EP-3689878-B1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS | MERCK SHARP & DOHME (NL) | 2021-10-06 | — | — | EP | disclosed |
| US-20210230166-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-10934296-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2021-03-02 | — | — | US | disclosed |
| EP-3689878-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK-INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2020-08-05 | — | — | EP | disclosed |
| US-20190276456-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2019-09-12 | — | — | US | disclosed |
| EP-3495368-A1 | (S)-4-(8-AMINO-3-(1-(BUT-2-YNOYL)PYRROLIDIN-2-YL)IMIDAZO[1,5-A]PYRAZIN-1-YL)-2-METHOXY-N-(PYRIDIN-2-YL)BENZAMIDE AS BTK-INHIBITOR | Merck Sharp & Dohme B.V. (NL) | 2019-06-12 | — | — | EP | disclosed |
| US-10239883-B2 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2019-03-26 | — | — | US | disclosed |
| US-20180179212-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2018-06-28 | — | — | US | disclosed |
| US-9790226-B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2017-10-17 | — | — | US | disclosed |
| US-9758524-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2017-09-12 | — | — | US | disclosed |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-9290504-B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2016-03-22 | — | — | US | disclosed |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-06-05 | — | — | US | disclosed |
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179212-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 237/4885RET 518/4885 |
| US-10934296-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | BTK, SYK, ABL1 | BTK 1/4885TNK2 237/4885RET 518/4885 |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | BTK 1/4885TNK2 287/4885RET 715/4885 |
| US-20210230166-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 237/4885RET 518/4885 |
| US-10239883-B2 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | BTK, SYK, ABL1 | BTK 1/4885TNK2 237/4885RET 518/4885 |
| US-20190276456-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 237/4885RET 518/4885 |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | BTK 1/4885TNK2 299/4885RET 704/4885 |
| US-20230331729-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885TNK2 237/4885RET 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.